# Montagu acquires majority stake in HTL from Bridgepoint

Montagu, a private equity firm, has acquired a majority stake in HTL, a pharmaceutical-grade biopolymer manufacturer, from Bridgepoint. Naxicap and Téthys Invest retain their minority shares.

- Type: Acquisition
- Announced: 2022-02-28
- Where: France
- Status: announced
- Products: pharmaceutical grade biopolymers
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Bridgepoint](https://endata.com/companies/6769.md) (partner)
- [Montagu](https://endata.com/companies/34954.md) (acquirer)
- [HTL](https://endata.com/companies/61324.md) (target)
- [Naxicap](https://endata.com/companies/61325.md) (investor)
- [Téthys Invest](https://endata.com/companies/61326.md) (investor)

## Sources

- [montagu.com](https://montagu.com/htl-announces-montagu-as-new-investor/), 2022-02-28: "HTL embodies all the characteristics of a French industrial success and perfectly represents the kind of high-potential healthcare companies at the heart of our investment strategy."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.